Nilotinib Ratiopharm

Nilotinib, the active ingredient in Nilotinib Ratiopharm, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia in chronic, accelerated, and blast phases. GNH USA supplies Nilotinib Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is a targeted tyrosine kinase inhibitor used in the management of chronic myeloid leukemia (CML). - Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and achieves cytogenetic and molecular responses. - Chronic myeloid leukemia (accelerated phase): helps control disease progression and improve survival. - Chronic myeloid leukemia (blast crisis): provides disease control when combined with other therapies.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild skin irritation or redness. - Nausea: feeling of sickness or urge to vomit. - Diarrhea: loose or watery stools. - Elevated liver enzymes: increase in ALT/AST levels.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusion, heart attack, or stroke. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Nilotinib, clinicians should consider several safety precautions. - Cardiac monitoring: assess cardiovascular risk and monitor for ischemic events. - Liver function: evaluate baseline hepatic enzymes and repeat monitoring during therapy. - Electrolyte balance: check serum potassium and magnesium levels regularly. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and avoid breastfeeding. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Nilotinib interacts with several medications that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib plasma levels, increasing risk of serious adverse events. - Proton pump inhibitors (e.g., omeprazole) taken concomitantly: can reduce absorption and lower efficacy. - Antacids containing aluminum or magnesium: may decrease drug bioavailability.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Nilotinib concentrations, reducing therapeutic effect. - Statins (e.g., simvastatin, atorvastatin): increased risk of myopathy; dose adjustment may be needed. - Anticoagulants (e.g., warfarin): monitor INR as Nilotinib may affect coagulation parameters.